**EKOS**<sup>™</sup> Endovascular System



**ACUTE INTERMEDIATE-RISK PE CASE STUDY IN OBESE YOUNG PATIENT:** 

# **EKOS THERAPY WITH A LOW-DOSE OPTALYSE PROTOCOL**

#### **PHYSICIAN**

Amit J Dwivedi, MD, FACS, RPVI, RVT Professor and Chief Division of Vascular and Endovascular Surgery University of Louisville, KY

#### **PATIENT HISTORY**

- 34 yo Caucasian male with BMI of 45 presented with history of sudden onset shortness of breath, worse with exertion; job requires patient to be physical
- No history of leg swelling or pain
- No previous history of DVT, PE, or hypercoagulable state
- Venous US: Thrombus within the mid/distal right and left SFV and popliteal vein
- PE: respiratory distress, pulse: 107, RR: 27, O2 saturation: 89% on 2LO2
- EKG: sinus tachycardia

### **DIAGNOSTICS**


- Extensive bilateral PE
- RV/LV ratio: 2.0

- · Signs of right heart strain including -
  - Deviation of the interventricular septum
  - Dilatation of the right ventricle
  - Dilatation of the main pulmonary artery

#### TREATMENT TECHNIQUE

- Trackability of sheaths in morbidly obese patient can be very difficult so mechanical thrombectomy not preferred as minimum sheath requirements are 12 Fr to 24 Fr
- EKOS treatment as per OPTALYSE Protocol tPA infusion 1mg/hr x 6 hours in each EKOS catheter
- Procedure details:
  - Two 6 French sheaths placed in right common femoral vein with **US-guided access**
  - Easy trackability of two 12 cm EKOS catheters placed in the right and left pulmonary arteries
  - Pulmonary artery pressure: 46/12
- Enoxaparin 1mg/kg SQ q12 administered to patient during hospital course
- On following day, patient discharged on Apixaban





#### TREATMENT NOTES & OUTCOME

- Morbidly obese patient with bilateral intermediate-high risk PE can be treated with excellent safety and efficacy with significant cost savings to the hospital
- Trackability of EKOS catheters in dilated RV to LV make it an easy and durable option in morbidly obese patient
- Patient back to his work routine in 1 week
- EKOS Rx was performed as per OPTALYSE Protocol on this morbidly obese patient leads to
  - Ease of treatment
  - Low risk of complications
  - Reduced hospital length of stay
  - Early return to work



## For more information, please visit www.bostonscientific.com/ekos

#### **EKOS® ACOUSTIC PULSE THROMBOLYSIS TREATMENT**

CAUTION: Federal law (USA) restricts this device to sale by or on the order of a physician. Rx only. Prior to use, please see the complete "Directions for Use" for more information on Indications, Contraindications, Warnings, Precautions, Adverse Events, and Operator's Instructions. INDICATIONS FOR USE: The EkoSonic Endovascular System is indicated for the: Ultrasound facilitated, controlled and selective infusion of physician-specified fluids, including thrombolytics, into the vasculature for the treatment of pulmonary embolism. • Infusion of solutions into the pulmonary arteries. • Controlled and selective infusion of physician specified fluids, including thrombolytics, into the peripheral vasculature. All therapeutic agents utilized with the EkoSonic Endovascular System should be fully prepared and used according to the instruction for use of the specific therapeutic agent. CONTRAINDICATIONS: Not designed for peripheral vasculature dilation purposes. • This system is contraindicated when, in the medical judgment of the physician, such a procedure may compromise the patient's condition. POTENTIAL COMPLICATIONS: Vessel perforation or rupture • Distal embolization of blood clots • Vessel spasm • Hemorrhage • Hematoma • Pain and tenderness • Sepsis/Infection • Thrombophlebitis • Tricuspid and pulmonic valve damage • Pulmonary infarct due to tip migration and spontaneous wedging, air embolism, and/or thromboembolism • Right bundle branch block and complete heart block • Intimal disruption • Arterial dissection • Vascular thrombosis • Drug reactions • Allergic reaction to contrast medium • Arteriovenous fistula • Thromboembolic episodes • Amputation • Pneumothorax • Perforation of the pulmonary artery. • Cardiac Arrhythmias – most frequently occurring during placement, removal or following displacement into the right ventricle. PI-726201-AA

**Peripheral Interventions** 300 Boston Scientific Way Marlborough, MA 01752-1234 www.bostonscientific.com

Advancing science for life™

To order product or for more information contact customer service at 1.888.272.1001 © 2021 Boston Scientific Corporation or its affiliates. All rights reserved. PI-1104008-AA

All trademarks are the property of their respective owners.